Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Synspira

Pre-clinical

Pre-clinical

Therapeutic Approach

Nutritional-GI

This program is studying SNSP003, a non-porcine (not pig-derived) enzyme replacement therapy for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from bacteria, and it does not contain any animal products. SNSP003 may improve dosing convenience by reducing pill burden compared to current porcine-based pancreatic enzyme replacement therapies (PERT). SNSP003 is also being developed in a formulation for pediatric and adult patients who are unable to swallow capsules.

Status

Laboratory studies to develop and test this compound are underway.

Sponsor

This program is sponosred by Synspira and partially funded by the Cystic Fibrosis Foundation.



Contact us about Synspira >